Prevalence of genotypic resistance mutations in patients with chronic hepatitis B (HBV) treated with entecavir and tenofovir in two reference centers in the North and Northeast of Brazil

dc.creatorPacheco, Sidelcina Rugieri
dc.creatorSchinoni, Maria Isabel
dc.creatorStocker, Andreas
dc.creatorParaná, Raymundo
dc.creatorReis, Mitermayer Galvão dos
dc.creatorSilva, Luciano Kalabric
dc.date2023-06-16T14:29:58Z
dc.date2023-06-16T14:29:58Z
dc.date2023
dc.date.accessioned2023-09-26T20:21:16Z
dc.date.available2023-09-26T20:21:16Z
dc.identifierPACHECO, Sidelcina Rugieri et al. Prevalence of genotypic resistance mutations in patients with chronic hepatitis B (HBV) treated with entecavir and tenofovir in two reference centers in the North and Northeast of Brazil. Archives of Medical Research, v. 11, n. 3, p. 1-9, 2023.
dc.identifier0188-4409
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/59055
dc.identifier10.18103/mra.v11i3.3473
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8854958
dc.descriptionFundação Maria Emília de Carvalho Freire.
dc.descriptionMutations of genotypic resistance to nucleotide analogues Entecavirand Tenofovirhave been described in patients undergoing treatment and virgins for hepatitis B virus. The present study demonstrated in a sample of 263 patients with chronic HBV from the North and Northeast of Brazil, a mutation rate of resistance to nucleotide analogues of 3.8% (10). Of the 10 patients who had genotypic resistance mutations, only 1 had no genotypic resistance mutation for the first line treatment for hepatitis B, entecavir and tenofovir.Due to the emergence of vaccine escape mutations and resistance mutations to antiviral treatment, and the severity of liver disease caused by HBV, screening for genetic mutations is important due to the impact on therapeutic management.
dc.formatapplication/pdf
dc.languageeng
dc.publisherElsevier
dc.rightsopen access
dc.subjectHepatite B
dc.subjectMutações genotípicas
dc.subjectEntecavir
dc.subjectTenofovir
dc.subjectHepatitis B
dc.subjectGenotypic mutations
dc.subjectEntecavir
dc.subjectTenofovir
dc.subjectHepatite B
dc.subjectMutação
dc.subjectGenética
dc.subjectTenofovir
dc.titlePrevalence of genotypic resistance mutations in patients with chronic hepatitis B (HBV) treated with entecavir and tenofovir in two reference centers in the North and Northeast of Brazil
dc.typeArticle


Este ítem pertenece a la siguiente institución